Corden Pharma Fribourg SA has 2,764 employees, according to Revelio Labs workforce intelligence data. The YoY growth rate is -3.6%.
Data source: Revelio Labs Coverage: Global workforce Latest update: September 2025
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Inositec was acquired by Vifor Pharma in 2021.
As of September 2025
Vifor Pharma
workforce metrics
Headcount
2.8k
Avg. Salary
$110.8k
Tenure
4.8yr
Growth Rate
-3.6%
Hiring Rate
Attrition Rate
For even more metrics data,
reach out to our sales team.
Interactive chart of Vifor Pharma annual worldwide employee count from 2023 to 2025.
Would you like to see the latest employee headcount data?
Would you like to see the latest employee geographic data?
Interactive chart of Vifor Pharma annual active job postings from 2023 to 2025.
Would you like to see the latest active job postings data?
Sentiment Topics
Would you like to see the latest employee sentiment data?